| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 44 |
| 1 | TACROLIMUS | 14 |
| 2 | CARBOPLATIN | 11 |
| 3 | PACLITAXEL | 11 |
| 4 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 11 |
| 5 | TACROLIMUS OINTMENT 0.1% | 11 |
| 6 | MYCOPHENOLATE MOFETIL | 10 |
| 7 | PREDNISOLONE | 10 |
| 8 | PREDNISOLONE ORAL | 10 |
| 9 | PREDNISOLONE ORAL SOLUTION | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPLONTERSEN | 1 | 0.0057 |
| 1 | PRALATREXATE | 1 | 0.0015 |
| 2 | RAMUCIRUMAB | 7 | 0.0011 |
| 3 | OMEPRAZOLE, SODIUM BICARBONATE | 1 | 0.0010 |
| 4 | LEVOLEUCOVORIN INJECTION | 3 | 0.0010 |
| 5 | LEVOLEUCOVORIN | 3 | 0.0008 |
| 6 | PEGFILGRASTIM-CBQV | 1 | 0.0007 |
| 7 | MINERAL OIL | 1 | 0.0007 |
| 8 | ONASEMNOGENE ABEPARVOVEC-XIOI | 1 | 0.0004 |
| 9 | RITUXIMAB-ABBS | 2 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 7 | 0.0011 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 44 | 0.0002 |
| 2 | Phosphodiesterase 3 Inhibitor [EPC] | 1 | 0.0002 |
| 3 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 4 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 2 | 0.0001 |
| 5 | Antisense Oligonucleotide [EPC] | 1 | 0.0001 |
| 6 | Antimycobacterial [EPC] | 2 | 0.0001 |
| 7 | Lipid-based Polyene Antifungal [EPC] | 1 | 0.0001 |
| 8 | Platinum-based Drug [EPC] | 20 | 0.0001 |
| 9 | Complement Inhibitor [EPC] | 4 | 0.0001 |